RespireRx Pharmaceuticals Inc (fka RSPI)

[bladerunner1717]

Fred,

The $160 million figure that I used came from 1Q report that reported cash at the end of that quarter. The CC yesterday refers to cash at the end of their fiscal year. (I'm not sure why the cash burn is that high. I would have expected that there would be a drop in the cash burn, since the development of the hepatitis C drug, valopicitabine, has been halted. But then again, I don't know the cash burn before the trial was halted.) I think Dew would know the answer to that question.


Bladerunner